|
Compound class:
Antibody
Comment: NP137 (Netris Pharma) is a clinical lead anti-netrin 1 IgG1 monoclonal antibody [1]. It was developed as a novel anti-cancer therapeutic. The netrin 1 epitope recognised by NP137 is 90% homologous to the analogous region in netrin 3, suggesting cross-reactivity, and the potential for NP137 to be deployed against netrin 3-expressing tumours [2]. Antibody binding disrupts the netrin 1/UNC5B interaction.
|
| No information available. |
Summary of Clinical Use  |
| NP137 has a dvanced to clinical trials in which it will be evaluated as an addition to standard anti-cancer therapies including checkpoint inhibitor antibodies and/or chemotherapy regimens, for advanced solid tumours. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04652076 | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab | Phase 1/Phase 2 Interventional | NETRIS Pharma | ||
| NCT02977195 | First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors | Phase 1 Interventional | Centre Leon Berard | ||
| NCT05605496 | NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies | Phase 2 Interventional | Centre Leon Berard | ||
